Product Description
Matriks Biotek SHIKARI® Q-ATI (Quantitative)
Enzyme immunoassay for the quantitative determination of specific antibodies to infliximab in human serum and plasma with confirmation.
Infliximab (Remicade) was associated to the development of anti-Infliximab antibodies, even some were reported to be neutralizing, in various percentages of patients during therapy with the drug Remicade®. This might lead to severe complications. The Matriks Biotek Shikari Q-ATI ELISA Kit can be efficiently used for monitoring anti-Infliximab antibodies.
Quantitative Specifications:
| Required Volume (µl) | 20 |
| Total Time (min) | 140 |
| Sample | Serum, Plasma |
| Sample Number | 96 |
| Detection Limit (ng/mL) | 15 |
| Spike Recovery (%) | Between 85-115 |
| Shelf Life (year) | 1 |
Documentation
Download IFU (Quantitative)
Download MSDS (Quantitative)
Please note that the documentation provided is for reference use only. For the most updated version, please contact us.
For Research Use Only
Manufactured by Matriks Biotek Co.
| Questions about this product? Ready to place an order? Email us at orders@iwai-chem.com or give us a call: (650) 486-1541 |
